Navaneetha Nambigari, Ravi Kumar Vuradi and Satyanarayanasirasani
Osmania University, India
Scientific Tracks Abstracts: J Clin Trials
Disruption of the regulation of normal tumor suppressor genes and activation of oncogenes lead to abnormal growth i.e., development of cancer. Platinum complexes represent one of the most successful families of clinically used metalbased anticancer drugs; other transition metal complexes such as ruthenium complexes generate interest as antitumor agents. Ruthenium complexes have shown great potential and remain the subject of extensive drug discovery efforts. Transition metals can provide several interesting complex structures capable of apoptosis & forms an interesting area of research. The present work focuses on a series of mononuclear ruthenium (ii) polypyridyl complexes with n, n-donor ligands (then = 1, 10 phenanthroline, bpy = 2, 2â?? bipyridine, dmb = 4, 4â??-dimethyl 2, 2â?? bipyridine and an intercalating ligands (bnpip= 2-(4-butoxy- 3-nitrophenyl)-1h-imidazo [4, 5-f][1, 10] phenanthroline, synthesized and characterized. The binding abilities of ruthenium complexes were investigated using UV-visible and fluorescence studies. The mode of binding was confirmed by viscosity experiment. Experimental results suggested that they can bind through intercalative mode with DNA having different binding constant. The in vitro assays were used to determine the cytotoxicity and apoptotic activities of the complexes. The significant in vitro activity observed for these complexes show promising findings for future in vivo cytotoxicity and anti-proliferative evaluation.
